Establishment and characterization of NCC-SS3-C1: a novel patient-derived cell line of synovial sarcoma
Establishment and characterization of NCC-SS3-C1: a novel patient-derived cell line of synovial sarcoma
复制标题
NCC-SS3-C1 的建立和表征：一种新型的患者来源的滑膜肉瘤细胞系
DOI：
10.1007/s13577-020-00354-6
复制
发表时间：
2020
期刊：
影响因子：
4.3
通讯作者：
Kondo Tadashi
中科院分区：
文献类型：
--
作者：
Yoshimatsu Yuki;Noguchi Rei;Tsuchiya Ryuto;Sei Akane;Sugaya Jun;Iwata Shintaro;Yoshida Akihiko;Kawai Akira;Kondo Tadashi
滑膜肉瘤是一种罕见的恶性肿瘤间质起源，其特征是染色体易位，t（X;18）（p11.2;q11.2）。广泛的手术切除与放射和细胞毒性化疗被确定为标准治疗;然而，滑膜肉瘤仍然是一种预后不良的高级别肉瘤，目前正在开发新的抗癌药物和免疫方法。患者来源的细胞系是基础和临床前研究的关键工具。然而，只有少数患者来源的滑膜肉瘤细胞系可从细胞库中公开获得。因此，本研究的目的是建立和表征一种新型的滑膜肉瘤细胞系。利用从一名48岁女性患者手术切除的肿瘤组织，我们成功建立了一个细胞系，命名为NCC-SS 3-C1。NCC-SS 3-C1细胞携带SS 18-SSX 1融合基因，并表现出中度生长、球体形成和侵袭。我们使用NCC-SS 3-C1细胞检查了包括FDA批准的抗癌药物在内的小分子抗癌化合物的一系列增殖抑制作用，并鉴定了在低浓度下抑制NCC-SS 3-C1细胞增殖的抗癌药物。我们的结论是，NCC-SS 3-C1将是基础和临床前滑膜肉瘤研究的有用工具。
Synovial sarcoma is a rare malignancy of mesenchymal origin, characterized by a chromosomal translocation,t(X;18) (p11.2;q11.2). Wide surgical resection with radiation and cytotoxic chemotherapy is established as a standard treatment; however synovial sarcoma remains a high-grade sarcoma with poor prognosis, and novel anti-cancer agents and immunological approaches are currently being developed. The patient-derived cell line is a critical tool for basic and pre-clinical research. However, only a few patient-derived synovial sarcoma cell lines are publicly available from cell banks. Thus, the aim of this study was to establish and characterize a novel cell line for synovial sarcoma. Using a surgically resected tumor tissue from a 48-year-old female patient, we successfully established a cell line, named NCC-SS3-C1. NCC-SS3-C1 cells harbor anSS18-SSX1fusion gene and exhibit moderate growth, spheroid formation, and invasion. We examined a range of proliferation-inhibiting effects of small molecule anti-cancer compounds, including FDA-approved anti-cancer drugs, using NCC-SS3-C1 cells, and identified anti-cancer drugs which inhibited the proliferation of NCC-SS3-C1 cells at the low concentration. We concluded that NCC-SS3-C1 would be a useful tool for basic and pre-clinical synovial sarcoma research.